CC
GNCA

Centiva Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Centiva Capital’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,029
Closed -$62K – 217
2018
Q2 		$62K Buy
+9,029
New +$67.5K 0.01% 93

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Centiva Capital's GNCA Position: Q3 2018 in Review

Centiva Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2018, closing a stake of 9,029 shares — an estimated $62K sold.

Centiva Capital first reported a position in GNCA in Q2 2018 and held it in 1 quarter. The position peaked at $62K in Q2 2018. 48 funds tracked by Wall St. Rank hold GNCA as of Q3 2018.

  • Centiva Capital reported no remaining Genocea Biosciences, Inc. position as of Q3 2018 after selling out during the quarter.
  • Centiva Capital sold 9,029 Genocea Biosciences, Inc. shares in Q3 2018, an estimated $62K.
  • Centiva Capital first reported a position in Genocea Biosciences, Inc. in Q2 2018 and held it in 1 quarter.
  • Centiva Capital's Genocea Biosciences, Inc. position peaked at $62K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2018.

Based on Centiva Capital's 13F filing for Q3 2018, filed 14 Nov 2018.